Abstract
Ketazolam, a new, long-acting benzodiazepine, was compared to placebo in a four-week double-blind study in 77 psychiatric outpatients with moderate to severe anxiety. The average optimum dose of ketazolam was 58.6 mg (range, 25 to 125 mg) given in a single bedtime dose. Fifteen patients in the placebo group (41%) dropped out of the study, 12 because of ineffectiveness of the medication and 3 because of intolerable side effects. In the ketazolam group, 5 patients (13%) dropped out because of ineffectiveness of the medication. This difference between treatment groups was statistically significant. Ketazolam was significantly more effective than placebo in reducing symptomatology on 10 of 14 Hamilton Anxiety Rating Scale categories and total scores, the Physician's and Patient's Global Impressions, and the Patient's Self-Rating Symptom Scales. The average number of side effects per patient receiving ketazolam was less at every evaluation period than for patients receiving placebo.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 170-178 |
| Number of pages | 9 |
| Journal | Current Therapeutic Research - Clinical and Experimental |
| Volume | 24 |
| Issue number | 2 |
| State | Published - 1978 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Double-blind placebo-controlled trial of ketazolam in anxiety. / Bowden, C. L.
In: Current Therapeutic Research - Clinical and Experimental, Vol. 24, No. 2, 1978, p. 170-178.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Double-blind placebo-controlled trial of ketazolam in anxiety
AU - Bowden, C. L.
PY - 1978
Y1 - 1978
N2 - Ketazolam, a new, long-acting benzodiazepine, was compared to placebo in a four-week double-blind study in 77 psychiatric outpatients with moderate to severe anxiety. The average optimum dose of ketazolam was 58.6 mg (range, 25 to 125 mg) given in a single bedtime dose. Fifteen patients in the placebo group (41%) dropped out of the study, 12 because of ineffectiveness of the medication and 3 because of intolerable side effects. In the ketazolam group, 5 patients (13%) dropped out because of ineffectiveness of the medication. This difference between treatment groups was statistically significant. Ketazolam was significantly more effective than placebo in reducing symptomatology on 10 of 14 Hamilton Anxiety Rating Scale categories and total scores, the Physician's and Patient's Global Impressions, and the Patient's Self-Rating Symptom Scales. The average number of side effects per patient receiving ketazolam was less at every evaluation period than for patients receiving placebo.
AB - Ketazolam, a new, long-acting benzodiazepine, was compared to placebo in a four-week double-blind study in 77 psychiatric outpatients with moderate to severe anxiety. The average optimum dose of ketazolam was 58.6 mg (range, 25 to 125 mg) given in a single bedtime dose. Fifteen patients in the placebo group (41%) dropped out of the study, 12 because of ineffectiveness of the medication and 3 because of intolerable side effects. In the ketazolam group, 5 patients (13%) dropped out because of ineffectiveness of the medication. This difference between treatment groups was statistically significant. Ketazolam was significantly more effective than placebo in reducing symptomatology on 10 of 14 Hamilton Anxiety Rating Scale categories and total scores, the Physician's and Patient's Global Impressions, and the Patient's Self-Rating Symptom Scales. The average number of side effects per patient receiving ketazolam was less at every evaluation period than for patients receiving placebo.
UR - http://www.scopus.com/inward/record.url?scp=0018235659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018235659&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0018235659
VL - 24
SP - 170
EP - 178
JO - Current Therapeutic Research
JF - Current Therapeutic Research
SN - 0011-393X
IS - 2
ER -